Article

Immune thrombocytopenic purpura in a patient with multiple sclerosis treated with natalizumab

Baylor College of Medicine, Houston, TX 77054, USA.
Neurology (Impact Factor: 8.3). 08/2011; 77(5):505-7. DOI: 10.1212/WNL.0b013e318227b23f
Source: PubMed
1 Follower
 · 
81 Views
  • Multiple Sclerosis 09/2014; 21(2). DOI:10.1177/1352458514546516 · 4.86 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Summary A 52-year-old woman with a 10-year history of relapsing-remitting multiple sclerosis (RRMS) was started on natalizumab after she developed side effects for interferon β-1a and glatiramer acetate. The patient presented with acute severe infusion reaction after the third treatment with natalizumab, developing whole-body purpura. Laboratory testing revealed progressive worsening thrombocytopenia up to 3 weeks following natalizumab discontinuation. Platelet antibodies to platelet-specific antigen as well as antibodies against natalizumab were positive. Bone marrow biopsy was negative. The patient was diagnosed with drug-induced immune thrombocytopenia (DITP) as a rare case of natalizumab side effect which was treated with intravenous methylprednisolone followed by rituximab with successful resolution of thrombocytopenia. The patient had a stable course of RRMS with no relapses and no brain MRI changes at 2 years after initiation of rituximab.
    Case Reports 05/2014; 2014. DOI:10.1136/bcr-2013-203313
  • [Show abstract] [Hide abstract]
    ABSTRACT: Natalizumab is a monoclonal therapeutic antibody that inhibits migration of lymphocytes into the central nervous system (CNS) by blocking integrins. Several clinical trials have shown an excellent efficacy in the treatment of relapsing remitting multiple sclerosis. This efficacy is also underlined by postmarketing data of patients with a more aggressive disease compared with the clinical trials. Certain patients might even improve during natalizumab treatment. These positive effects have to be balanced against potential adverse events. In this respect, allergic reactions, hematologic abnormalities, melanoma, lymphoma, infections, and most importantly, progressive multifocal leukoencephalopathy (PML) are discussed. A special emphasis is put on the risk stratification algorithm for PML and approaches for PML treatment. Further, patient and disease characteristics are discussed that might prompt the start or cessation of natalizumab. Finally, data on how to continue after stopping natalizumab are summarized.
    Seminars in Neurology 02/2013; 33(1):26-36. DOI:10.1055/s-0033-1343793 · 1.78 Impact Factor